title: Clinical outcome with half-dose depot triptorelin is the same as reduced-dose daily buserelin in a long protocol of controlled ovarian stimulation for ICSI/embryo transfer: a randomized double-blind clinical trial (NCT00461916).
abstract: BACKGROUND
  Traditional doses of depot GnRH agonist may be excessive for ovarian stimulation. We compared half-dose depot triptorelin (Group I) with reduced-dose daily buserelin (Group II) in a long protocol ICSI/embryo transfer through a double-blind randomized clinical trial.
  
  
  METHODS
  Controlled ovarian stimulation (COS) was started by a pretreatment with oral contraceptives for 21 days. Then, 182 patients were randomized into two groups of 91. Group I received 1.87 mg triptorelin depot i.m. followed by daily s.c. injections of saline. Group II (reduced-dose protocol) received a bolus injection of i.m. saline followed by daily s.c. injections of 0.5 mg buserelin, which was then reduced to 0.25 mg at the start of human menopausal gonadotrophin stimulation. When transvaginal ultrasound showed at least two follicles of 16-20 mm diameter, HCG was given and ICSI was performed 40-42 h later.
  
  
  RESULTS
  No significant differences were seen in the mean (SD) number of follicles at HCG administration, as our primary outcome [10.3 (4.4) in Group I versus 11.1 (4.2) in Group II, P = 0.180, mean difference = 0.86, 95% confidence interval 0.39-2.11]. The other early results of COS, clinical and ongoing pregnancy rates, or early pregnancy loss were also not significantly different between the groups. Group I endured longer stimulation period [11.2 (1.8) days versus 10.6 (1.9), P = 0.030].
  
  
  CONCLUSIONS
  Clinical outcomes were not significantly different between Group I and Group II.
authors.affiliation: Department of Obstetrics and Gynecology, Dr. Shariati Hospital, Medical Sciences/University of Tehran, North Kargar Avenue, Tehran 14114, Iran.
authors.forename: Leili
authors.initials: L
authors.lastname: Safdarian
authors.forename: Farnoosh Soltani
authors.initials: FS
authors.lastname: Mohammadi
authors.forename: Ashraf
authors.initials: A
authors.lastname: Alleyassin
authors.forename: Marzieh
authors.initials: M
authors.lastname: Aghahosseini
authors.forename: Alipasha
authors.initials: A
authors.lastname: Meysamie
authors.forename: Eiman
authors.initials: E
authors.lastname: Rahimi
mesh_terms: D000328:Adult; D002064:Buserelin / Q000008:administration & dosage*; D003692:Delayed-Action Preparations / Q000008:administration & dosage; D004311:Double-Blind Method; D004624:Embryo Transfer; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage*; D006801:Humans; D008186:Luteolytic Agents / Q000008:administration & dosage*; D010062:Ovulation Induction / Q000379:methods*; D011247:Pregnancy; D020554:Sperm Injections, Intracytoplasmic; D016896:Treatment Outcome; D017329:Triptorelin Pamoate / Q000008:administration & dosage*
chemical_list: D003692:Delayed-Action Preparations; D005300:Fertility Agents, Female; D008186:Luteolytic Agents; D017329:Triptorelin Pamoate; D002064:Buserelin